F. Barros

407 total citations
9 papers, 312 citations indexed

About

F. Barros is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, F. Barros has authored 9 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in F. Barros's work include HER2/EGFR in Cancer Research (4 papers), Cell Adhesion Molecules Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). F. Barros is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Cell Adhesion Molecules Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). F. Barros collaborates with scholars based in United Kingdom, Spain and Egypt. F. Barros's co-authors include Ian O. Ellis, Andrew R. Green, Emad A. Rakha, Desmond G. Powe, Mohammed A. Aleskandarany, Keith Neal, Ahmed Benhasouna, Jorge S. Reis‐Filho, Stephen Chan and Christopher C. Nolan and has published in prestigious journals such as British Journal of Cancer, International Journal of Cancer and European Journal of Cancer.

In The Last Decade

F. Barros

9 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Barros United Kingdom	8	159	128	128	72	45	9	312
Kyoungyul Lee South Korea	9	200 1.3×	96 0.8×	92 0.7×	88 1.2×	74 1.6×	18	345
Rocío Vicario Spain	7	157 1.0×	172 1.3×	74 0.6×	78 1.1×	36 0.8×	8	395
Kimberly B. Monahan United States	5	174 1.1×	172 1.3×	51 0.4×	29 0.4×	90 2.0×	6	324
Irene García‐Palmero Spain	12	131 0.8×	249 1.9×	102 0.8×	22 0.3×	47 1.0×	14	415
Mari Hosonaga Japan	8	196 1.2×	135 1.1×	108 0.8×	36 0.5×	119 2.6×	27	338
Eian Caulder United States	7	236 1.5×	192 1.5×	58 0.5×	62 0.9×	25 0.6×	11	385
Yaning He China	10	214 1.3×	208 1.6×	153 1.2×	47 0.7×	82 1.8×	16	423
Steffen Dickopf Germany	6	218 1.4×	276 2.2×	175 1.4×	68 0.9×	51 1.1×	9	459
Jingtong Zhai China	10	169 1.1×	110 0.9×	105 0.8×	28 0.4×	75 1.7×	21	334
Anita Welk Germany	6	175 1.1×	154 1.2×	67 0.5×	24 0.3×	51 1.1×	7	321

Countries citing papers authored by F. Barros

Since Specialization

Citations

This map shows the geographic impact of F. Barros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Barros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Barros more than expected).

Fields of papers citing papers by F. Barros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Barros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Barros. The network helps show where F. Barros may publish in the future.

Co-authorship network of co-authors of F. Barros

This figure shows the co-authorship network connecting the top 25 collaborators of F. Barros. A scholar is included among the top collaborators of F. Barros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Barros. F. Barros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Green, Andrew R., F. Barros, Tarek M. Abdel-Fatah, et al.. (2014). HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Research and Treatment. 145(1). 33–44. 28 indexed citations

Barros, F., Tarek M.A. Abdel-Fatah, Paul M. Moseley, et al.. (2014). Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast Cancer Research and Treatment. 144(2). 273–285. 16 indexed citations

Green, Andrew R., Des G. Powe, Emad A. Rakha, et al.. (2013). Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. British Journal of Cancer. 109(7). 1886–1894. 30 indexed citations

Aleskandarany, Mohammed A., Andrew R. Green, Ahmed Benhasouna, et al.. (2012). Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Research. 14(1). R3–R3. 105 indexed citations

Menéndez, Sofía T., Juan P. Rodrigo, M. Ángeles Villaronga, et al.. (2012). 800 Role of HERG1 Potassium Channel in Both Malignant Transformation and Disease Progression in Head and Neck Carcinomas. European Journal of Cancer. 48. S191–S191. 1 indexed citations

Barros, F., Desmond G. Powe, Ian O. Ellis, & Andrew R. Green. (2010). Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology. 56(5). 560–572. 58 indexed citations

Storr, Sarah J., Caroline M. Woolston, F. Barros, et al.. (2010). Calpain‐1 expression is associated with relapse‐free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. International Journal of Cancer. 129(7). 1773–1780. 34 indexed citations

Peñaranda, José Manuel Suárez, et al.. (2001). Analysis of 2 Antiapoptotic Factors in Gliomas. Archives of Pathology & Laboratory Medicine. 125(2). 218–223. 14 indexed citations

Peñaranda, José Manuel Suárez, et al.. (2000). Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study.. PubMed. 44(4). 203–9; discussion 209. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact